Myo-inositol in autoimmune thyroiditis, and hypothyroidism

Area of Science:

• Endocrinology
• Immunology
• Molecular Biology

Background:

• Myo-inositol (Myo-Ins) is crucial for thyroid function and autoimmunity, acting as a precursor for phosphoinositides involved in cellular signaling.
• Phosphatidylinositol (3,4,5)-trisphosphate (PIP-3) signaling, regulated by phosphatidyl inositol 3 kinases (PI3K), influences immune cell behavior and is implicated in autoimmune disorders.
• Cytokines modulate Myo-Ins levels in thyroid cells, highlighting a link between immune signaling and Myo-Ins metabolism.

Purpose of the Study:

• To evaluate the effect of Myo-inositol plus seleniomethionine (Myo-Ins + Se) on thyroid function and autoimmunity in patients with subclinical hypothyroidism.
• To investigate the immune-modulatory effects of Myo-Ins + Se treatment by analyzing serum CXCL10 levels.

Main Methods:

• A clinical study involving patients with subclinical hypothyroidism due to autoimmune thyroiditis.
• Treatment with Myo-inositol plus seleniomethionine (Myo-Ins + Se).
• Monitoring of thyroid-stimulating hormone (TSH), antithyroid autoantibodies, and serum CXCL10 levels before and after treatment.

Main Results:

• Treatment with Myo-Ins + Se led to a significant decline in TSH levels.
• A reduction in antithyroid autoantibodies was observed post-treatment.
• Serum CXCL10 levels decreased, indicating an immune-modulatory effect of the intervention.

Conclusions:

• Myo-inositol plus seleniomethionine may be beneficial in managing subclinical hypothyroidism associated with autoimmune thyroiditis.
• The observed decline in CXCL10 supports the role of Myo-Ins in modulating immune responses within the thyroid.
• Further large-scale studies are warranted to confirm these findings and explore effects on quality of life and chemokine mechanisms.